Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66
Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. PTHS | 0.00 |
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:
PTHS) with a Outperform and raises the price target from $62 to $66.
